Today the American Society of Neuroradiology published Introducing BrainSee, a summary of study results presenting the 91 percent accuracy rate of the new AI-powered and patented technology by Darmiyan Inc. that detects Alzheimer’s disease at early stages of disease development. According to the publication made public at ASNR’s annual meeting, subtitled, A Novel, MRI-based Virtual Microscope Technology for Non-invasive Prognosis of Amnestic MCI in Clinics and Clinical trials, leading experts in the US and Canada confirmed the high test, retest reliability of the technology available for research on early detection of Alzheimer’s related mild cognitive impairment through a non-invasive method. Investigators noted that BrainSee is due to facilitate development of therapeutics for mild cognitive impairment and AD that can fill the clinical gaps.
“I look forward to making widely available BrainSee, an imaginative new method for noninvasively illuminating and detecting Alzheimer’s at stages where intervention might be possible,” said Dr. Alexander Mark, Medical Director MedStar Imaging Network Rockville and Chevy Chase. BrainSee by Darmiyan, a California-based company, combines the latest in computational neuroscience and digital health technologies with medical imaging to provide a unique enterprise software solution to address mild cognitive impairment before dementia.
“Alzheimer’s disease is the leading cause of dementia, with 50 million people suffering from it worldwide. Three times as many, roughly 150 million people, worry that their sudden onset of memory loss or cognitive impairment is an early symptom of Alzheimer’s disease. In almost a third of worried patients, it’s not Alzheimer’s. We focus on extracellular space because it’s a frontier rich with information about the unseen early stages of mild cognitive impairment. Our goal with BrainSee is to help doctors provide reassurance and answer questions about disease progression: Will patients stabilize or improve? What time window do we have for planning? ” Dr. Padideh Kamali-Zare, CEO and Founder of Darmiyan, said.